Arcus Biosciences, Inc. — FY2021 Form 10-K
Reporting period: Fiscal year ended December 31, 2021. This is an annual report; standalone fourth-quarter results are not presented clearly in the supplied filing text.
Business context
Arcus is a clinical-stage biopharmaceutical company developing cancer therapies. It reported six investigational products in clinical development, with domvanalimab advancing in registrational studies. The company has no approved products and has never generated product-sale revenue. Its reported collaboration and license revenue comes primarily from Gilead and Taiho agreements.
Financial highlights
| Metric | FY2021 | FY2020 |
|---|---|---|
| Collaboration and license revenue | $382.9 million | $77.5 million |
| Research and development expense | $256.3 million | $159.3 million |
| General and administrative expense | $72.3 million | $42.4 million |
| Operating income (loss) | $54.2 million | $(124.2) million |
| Net income (loss) | $52.8 million | $(122.9) million |
| Basic / diluted EPS | $0.76 / $0.71 | $(2.24) / $(2.24) |
| Net cash from (used in) operating activities | $(256.2) million | $111.2 million |
- Revenue increased by $305.4 million, primarily due to Gilead program opt-ins and collaboration revenue. The filing reports $328.8 million of 2021 license revenue for domvanalimab; total collaboration and license revenue also includes other Gilead and Taiho amounts.
- Operating expenses rose 63% overall as clinical development, manufacturing, staffing and infrastructure expanded. R&D expense increased 61%; G&A expense increased 70%.
- Net income and the positive operating result reflect collaboration/license accounting, not product sales. The filing does not provide a meaningful product gross margin; the reported operating margin was approximately 14% and net margin approximately 14%, but these are heavily affected by collaboration revenue.
- Cash, cash equivalents and investments totaled $681.3 million at year-end. A $725 million Gilead option payment was receivable at December 31 and received in January 2022; management then estimated approximately $1.4 billion in cash, cash equivalents and investments and runway into 2026.
- Year-end current assets were $1.262 billion, including the $744.6 million collaboration-partner receivable; current liabilities were $166.1 million. Total liabilities were $750.4 million, including deferred revenue and lease obligations.
- No conventional borrowings are identified in the supplied financial statements. The company reported a $5.3 million liability for future royalties and $158.5 million of undiscounted operating lease payments through 2031.
- Capital expenditures for property and equipment were $26.1 million. Operating cash use was $256.2 million, versus operating cash inflow of $111.2 million in 2020; the prior-year inflow included significant Gilead-related cash receipts.
Material changes and notable items
- Gilead exercised options covering three programs—anti-TIGIT (domvanalimab and AB308), adenosine receptor antagonist (etrumadenant), and CD73 inhibitor (quemliclustat)—for $725 million, received in January 2022. The agreement also provides for shared development costs and U.S. co-promotion rights, subject to terms, as well as ex-U.S. royalties.
- The $725 million payment is a major liquidity event but is not the same as recurring product revenue. At year-end, the company also reported $559.2 million of deferred revenue under the amended Gilead agreement.
- R&D reimbursements from collaboration partners reduced R&D expense by $24.9 million in 2021, up from $3.4 million in 2020.
- Arcus reported a $52.8 million net profit in 2021 after losses of $122.9 million in 2020 and $84.7 million in 2019. It had an accumulated deficit of $275.4 million at year-end and expects substantial operating losses as development advances.
- The company issued 5.65 million shares to Gilead in February 2021 for approximately $220.3 million net of offering costs. Gilead held about 19.5% of outstanding shares at year-end and could increase its ownership to 35% under its purchase rights.
Outlook, commentary and risks
- Management expects increasing R&D and administrative spending as it advances programs into later-stage trials, builds capabilities and supports collaboration programs. It stated that year-end resources plus the January 2022 Gilead payment should fund planned operations into 2026; this is an estimate based on assumptions and is not guaranteed.
- Management planned additional domvanalimab Phase 3 studies and further etrumadenant and quemliclustat studies in 2022, with ARC-7 and ARC-8 data expected in the second half of 2022 and initial AB521 data in the first half of 2022. These are forward-looking plans, not assured outcomes.
- Interim ARC-7 results showed encouraging activity for both domvanalimab combinations versus zimberelimab alone, with the triplet numerically ahead of the doublet; the filing cautions that interim data may change. No unexpected safety signals were reported in that interim analysis.
- In January 2022, Arcus said the etrumadenant arm in ARC-4 did not show differentiated activity versus the control and that this setting would be deprioritized.
- Key risks include clinical-trial failure or delay, safety findings, intense competition, dependence on Gilead and other partners, single-source manufacturing and supply-chain exposure, COVID-19 impacts, regulatory and reimbursement uncertainty, and intellectual-property disputes. The company also cited WuXi Biologics’ placement on the U.S. Unverified List, while stating it did not anticipate an impact to 2022 manufacturing plans at that time.
- There were no material legal proceedings disclosed. Ernst & Young issued unqualified audit opinions on the financial statements and internal control over financial reporting; management also concluded disclosure controls and internal controls were effective as of year-end.
Important facts for investors to verify
- Confirm receipt and availability of the $725 million Gilead payment and reconcile it to the year-end receivable and post-year-end liquidity.
- Assess how much future revenue recognition depends on satisfying Gilead performance obligations, including the $559.2 million deferred revenue balance, and review the judgments used to allocate transaction price.
- Track operating cash burn, rising trial and infrastructure costs, collaboration reimbursements, and whether management’s runway estimate remains appropriate.
- Review final and updated clinical results, especially ARC-7 and ARC-8, and distinguish preliminary efficacy observations from registrational evidence and established safety profiles.
- Monitor Gilead’s governance, ownership and program-development role, as well as Taiho territorial rights, partner cost sharing, royalties and any future option or milestone payments.
- Evaluate supply continuity and concentration at third-party manufacturers, including WuXi Biologics, alongside the company’s lease commitments and potential future financing or dilution.